Sonja Zweegman

List of Publications by Year
in descending order

231	12,871	50276	26613
papers	citations	46 h-index	107 g-index

232	232	232	11284
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide. Haematologica, 2022, 107, 437-445.	3.5	63
2	Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia, 2022, 36, 1066-1077.	7.2	39
3	Sexual problems in patients with hematological diseases: a systematic literature review. Supportive Care in Cancer, 2022, 30, 4603-4616.	2.2	2
4	Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile. Journal of Clinical Oncology, 2022, 40, 3132-3150.	1.6	13
5	Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands. Blood Cancer Journal, 2022, 12, 41.	6.2	6
6	Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinaseâ€‘2 (<scp>JAK2</scp>), in patients with myelofibrosis and low pretreatment platelet counts. British Journal of Haematology, 2022, 198, 317-327.	2.5	18
7	The EHA Research Roadmap: Malignant Lymphoid Diseases. HemaSphere, 2022, 6, e726.	2.7	1
8	Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. Journal of Clinical Oncology, 2022, 40, 3406-3418.	1.6	115
9	Reply to: â€œDiscussing sexuality in cancer care: towards personalized information for cancer patients and survivorsâ€. Supportive Care in Cancer, 2021, 29, 535-537.	2.2	3
10	Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison. Immunotherapy, 2021, 13, 143-154.	2.0	9
11	A population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL in The Netherlands. Leukemia and Lymphoma, 2021, 62, 549-559.	1.3	5
12	Smartphone measurements of physical activity and fitness are associated with early trial discontinuation of patients in (hemato)oncology phase I/II clinical trials. Supportive Care in Cancer, 2021, 29, 3783-3792.	2.2	2
13	Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 2021, 35, 31-44.	7.2	79
14	First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018. Blood Cancer Journal, 2021, 11, 22.	6.2	5
15	Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer Journal, 2021, 11, 40.	6.2	46
16	Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood Cancer Journal, 2021, 11, 38.	6.2	36
17	Improving the identification of frail elderly newly diagnosed multiple myeloma patients. Leukemia, 2021, 35, 2715-2719.	7.2	5
18	Two decades of targeted therapies in acute myeloid leukemia. Leukemia, 2021, 35, 651-660.	7.2	33

#	Article	IF	Citations
19	Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates. Hemato, 2021, 2, 116-130.	0.6	2
20	Expert review on softâ€tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. British Journal of Haematology, 2021, 194, 496-507.	2.5	67
21	Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells. Cells, 2021, 10, 665.	4.1	8
22	Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncology, The, 2021, 22, e119-e130.	10.7	92
23	Deletion 17p: a matter of size and number?. Blood, 2021, 137, 1135-1136.	1.4	2
24	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncology, The, 2021, 22, e105-e118.	10.7	136
25	Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis. Clinical Cancer Research, 2021, 27, 3793-3803.	7.0	27
26	Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Advances, 2021, 5, 2196-2215.	5.2	56
27	Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial. HemaSphere, 2021, 5, e562.	2.7	20
28	Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant. HemaSphere, 2021, 5, e561.	2.7	11
29	Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma. Blood Advances, 2021, 5, 2165-2172.	5.2	9
30	The value of bone marrow, liver, and spleen imaging in diagnosis, prognostication, and follow-up monitoring of myeloproliferative neoplasms: a systematic review. Cancer Imaging, 2021, 21, 36.	2.8	3
31	V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma. Cancers, 2021, 13, 2219.	3.7	7
32	Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients. Cancers, 2021, 13, 2452.	3.7	11
33	Transplant-ineligible newly diagnosed multiple myeloma: Current and future approaches to clinical care: A Young International Society of Geriatric Oncology Review Paper. Journal of Geriatric Oncology, 2021, 12, 499-507.	1.0	7
34	Primary therapy and survival in patients with Burkitt lymphoma in The Netherlands: a population-based study, 1989-2018. Blood, 2021, 137, 2848-2851.	1.4	1
35	Phosphoproteomic Characterization of Primary AML Samples and Relevance for Response Toward FLT3-inhibitors. HemaSphere, 2021, 5, e606.	2.7	12
36	Survival in Primary Myelofibrosis: A Population-based Analysis in the Netherlands. HemaSphere, 2021, 5, e595.	2.7	1

#	Article	IF	Citations
37	Addition by subtraction. Blood, 2021, 137, 3005-3006.	1.4	0
38	2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. Haematologica, 2021, 106, 2799-2812.	3.5	22
39	Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1963-1971.	2.3	14
40	Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study. Journal of Clinical Oncology, 2021, 39, 2758-2767.	1.6	25
41	Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2021, 39, 3613-3622.	1.6	25
42	Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options. Blood Reviews, 2021, 49, 100808.	5.7	27
43	Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. HemaSphere, 2021, 5, e528.	2.7	45
44	Personalized versus standard cognitive behavioral therapy for fear of cancer recurrence, depressive symptoms or cancer-related fatigue in cancer survivors: study protocol of a randomized controlled trial (MATCH-study). Trials, 2021, 22, 696.	1.6	1
45	Efficacy and safety of daratumumab combined with all-transretinoic acid in relapsed/refractory multiple myeloma. Blood Advances, 2021, 5, 5128-5139.	5.2	22
46	Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma. Journal of Clinical Medicine, 2021, 10, 4593.	2.4	11
47	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematology,the, 2021, 8, e934-e946.	4.6	46
48	A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma. Cancers, 2021, 13, 5606.	3.7	5
49	Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study. Blood Cancer Journal, 2021, 11, 178.	6.2	6
50	Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence. Science Translational Medicine, 2021, 13, eabh1962.	12.4	49
51	Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma. Haematologica, 2020, 105, e80-e83.	3.5	12
52	Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. Haematologica, 2020, 105, 1650-1659.	3.5	19
53	Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients. Haematologica, 2020, 105, e302-e306.	3.5	53
54	Ixazomib Treatment of IgA Multiple Myeloma With Hyperviscosity Syndrome. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e832-e835.	0.4	3

#	Article	IF	Citations
55	Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial. Lancet Haematology,the, 2020, 7, e874-e883.	4.6	20
56	Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmacoâ€economic assessment. European Journal of Haematology, 2020, 105, 635-645.	2.2	8
57	A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent antitumor response. Nature Cancer, 2020, 1, 1054-1065.	13.2	21
58	Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies. Cancers, 2020, 12, 3713.	3.7	23
59	Self-Reported Sexual Function in Sexually Active Male Hodgkin Lymphoma Survivors. Sexual Medicine, 2020, 8, 428-435.	1.6	9
60	Targeted Therapy With Immunoconjugates for Multiple Myeloma. Frontiers in Immunology, 2020, 11, 1155.	4.8	38
61	The characteristics, treatment patterns, and outcomes of older adults aged 80 and over with multiple myeloma. Journal of Geriatric Oncology, 2020, 11, 1274-1278.	1.0	12
62	Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer Journal, 2020, 10, 17.	6.2	75
63	Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities. Leukemia, 2020, 34, 1964-1966.	7.2	22
64	Preclinical Activity of JNJ-7957, a Novel BCMAÃ—CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab. Clinical Cancer Research, 2020, 26, 2203-2215.	7.0	53
65	Autologous haematopoietic stem-cell transplantation versus bortezomibâ€“melphalanâ€“prednisone, with or without bortezomibâ€“lenalidomideâ€“dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematology,the, 2020, 7, e456-e468.	4.6	244
66	Resistance Mechanisms towards CD38â˜Directed Antibody Therapy in Multiple Myeloma. Journal of Clinical Medicine, 2020, 9, 1195.	2.4	28
67	Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma. Journal of Geriatric Oncology, 2020, 11, 764-768.	1.0	26
68	Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. Haematologica, 2020, 105, 2879-2882.	3.5	20
69	Simplified frailty assessment tools: are we really capturing frailty or something else?. Leukemia, 2020, 34, 1967-1969.	7.2	11
70	Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia, 2020, 34, 2000-2011.	7.2	109
71	Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study. Blood, 2020, 136, 37-38.	1.4	16
72	Mechanisms of Resistance and Determinants of Response of the GPRC5D-Targeting T-Cell Redirecting Bispecific Antibody JNJ-7564 in Multiple Myeloma. Blood, 2020, 136, 8-9.	1.4	6

#	Article	IF	Citations
73	Daratumumab + bortezomib, thalidomide, and dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM): Baseline SLiM-CRAB based subgroup analysis of CASSIOPEIA.. Journal of Clinical Oncology, 2020, 38, 8538-8538.	1.6	4
74	T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma. Oncotarget, 2020, 11, 4076-4081.	1.8	23
75	The Prognostic Power of Gene Expression Profiling with Cytogentics and Routinely Acquired Serum Markers: SKY92 Combined with Revised ISS. Blood, 2020, 136, 24-25.	1.4	0
76	Ruxolitinib in Myelofibrosis and Baseline Thrombocytopenia in Real Life: Results in Dutch Patients and Review of the Literature. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 624-634.	0.4	0
77	Interobserver reproducibility of tumor uptake quantification with 89Zr-immuno-PET: a multicenter analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1840-1849.	6.4	11
78	⁸⁹Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo. Journal of Nuclear Medicine, 2019, 60, 1825-1832.	5.0	38
79	Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet, The, 2019, 394, 29-38.	13.7	665
80	Approach to the Older Adult With Multiple Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 500-518.	3.8	36
81	Relationship between CD34/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia. Leukemia Research, 2019, 81, 27-34.	0.8	11
82	Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptorâ€“engineered T Cells. Clinical Cancer Research, 2019, 25, 4014-4025.	7.0	110
83	Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial. Haematologica, 2019, 104, 2274-2282.	3.5	27
84	CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients. Journal of Translational Autoimmunity, 2019, 2, 100022.	4.0	16
85	CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia. Haematologica, 2019, 104, e100-e103.	3.5	90
86	Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e9-e11.	0.4	19
87	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 393, 253-264.	13.7	187
88	Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study. Blood, 2019, 134, 695-695.	1.4	14
89	Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study. Blood, 2019, 134, 692-692.	1.4	42
90	Comparative Efficacy and Safety of Bortezomib, Thalidomide, and Dexamethasone (VTd) without and with Daratumumab (D-VTd) from Cassiopeia Versus Vtd from Pethema/GEM in Patients with Newly Diagnosed Multiple Myeloma Using Propensity Score Matching (PSM). Blood, 2019, 134, 4740-4740.	1.4	1

#	Article	IF	Citations
91	Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study. Blood, 2019, 134, 693-693.	1.4	18
92	The Impact and Modulation of Microenvironment-Induced Immune Resistance Against CAR T Cell and Antibody Treatments in Multiple Myeloma. Blood, 2019, 134, 137-137.	1.4	10
93	Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study. Blood, 2019, 134, 704-704.	1.4	2
94	Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-NaÃ¯ve or were Previously Treated with Ruxolitinib. Blood, 2019, 134, 668-668.	1.4	16
95	Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX. Blood, 2019, 134, 4165-4165.	1.4	2
96	Phase 3 randomized study of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results.. Journal of Clinical Oncology, 2019, 37, 8003-8003.	1.6	6
97	Recommended patient information sheet on the impact of haematopoietic cell transplantation on sexual functioning and sexuality. Ecancermedicalscience, 2019, 13, 987.	1.1	5
98	Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib. Blood, 2019, 134, 2207-2207.	1.4	1
99	CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience. Expert Review of Clinical Immunology, 2018, 14, 197-206.	3.0	30
100	RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML. Blood, 2018, 131, 2485-2489.	1.4	22
101	Health-care professionalsâ€™ perspective on discussing sexual issues in adult patients after haematopoietic cell transplantation. Bone Marrow Transplantation, 2018, 53, 235-245.	2.4	13
102	A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma. Critical Reviews in Oncology/Hematology, 2018, 121, 74-89.	4.4	28
103	Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images. Molecular Imaging and Biology, 2018, 20, 1025-1034.	2.6	13
104	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 2018, 32, 1542-1560.	7.2	68
105	Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients. Haematologica, 2018, 103, e368-e371.	3.5	43
106	Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update. Drugs, 2018, 78, 19-37.	10.9	108
107	Ixazomib for the treatment of multiple myeloma. Expert Opinion on Pharmacotherapy, 2018, 19, 1949-1968.	1.8	42
108	Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. Lancet Haematology,the, 2018, 5, e479-e492.	4.6	25

#	Article	IF	Citations
109	European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica, 2018, 103, 1772-1784.	3.5	86
110	European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia, 2018, 32, 1883-1898.	7.2	81
111	The need for information among patients with hematological malignancies: Psychometric analyses of the 62-item Hematology Information Needs Questionnaire (HINQ-62). PLoS ONE, 2018, 13, e0201699.	2.5	3
112	Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia, 2018, 32, 1697-1712.	7.2	83
113	Lenalidomide As Maintenance Treatment for Patients with Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation: A Pharmacoeconomic Assessment in the Netherlands. Blood, 2018, 132, 3555-3555.	1.4	4
114	Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (IDd) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; First Interim Safety Analysis of the Phase II HOVON 143 Study. Blood, 2018, 132, 596-596.	1.4	19
115	Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients. Oncotarget, 2018, 9, 34009-34021.	1.8	17
116	Transcriptomics in Multiple Myeloma Demonstrates an Association between Survival and Expression of T Cell Co-Signaling Ligands in Bone Marrow Derived Myeloma Plasma Cells. Blood, 2018, 132, 241-241.	1.4	0
117	A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization. Molecular Therapy, 2017, 25, 1946-1958.	8.2	197
118	Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematology,the, 2017, 4, e317-e324.	4.6	243
119	Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. Haematologica, 2017, 102, 85-93.	3.5	46
120	Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncology, The, 2017, 18, e206-e217.	10.7	394
121	Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. Clinical Cancer Research, 2017, 23, 7498-7511.	7.0	134
122	Elderly patients with multiple myeloma: towards a frailty approach?. Current Opinion in Oncology, 2017, 29, 315-321.	2.4	77
123	(Immuno)proteasomes as therapeutic target in acute leukemia. Cancer and Metastasis Reviews, 2017, 36, 599-615.	5.9	29
124	Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. Leukemia Research, 2017, 63, 34-40.	0.8	18
125	Treatment and relative survival in very elderly patients with DLBCL in The Netherlands: a population-based study, 1989 to 2015. Blood Advances, 2017, 1, 1839-1841.	5.2	5
126	Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. PLoS ONE, 2017, 12, e0169828.	2.5	50

#	Article	IF	Citations
127	Bortezomib resistance in multiple myeloma is associated with increased serine synthesis. Cancer & Metabolism, 2017, 5, 7.	5.0	115
128	Central nervous system involvement by multiple myeloma: A multiâ€institutional retrospective study of 172 patients in daily clinical practice. American Journal of Hematology, 2016, 91, 575-580.	4.1	83
129	Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. Blood, 2016, 128, 2297-2306.	1.4	49
130	Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. Drugs, 2016, 76, 853-867.	10.9	34
131	Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Blood, 2016, 127, 1109-1116.	1.4	102
132	CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood, 2016, 128, 959-970.	1.4	286
133	Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy. Journal of Hematology and Oncology, 2016, 9, 82.	17.0	22
134	Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica, 2016, 101, 926-931.	3.5	118
135	Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leukemia and Lymphoma, 2016, 57, 2071-2076.	1.3	30
136	Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial. Blood, 2016, 128, 1141-1141.	1.4	7
137	The Relationship of Response on Time to Next Treatment Based on Evidence from Two RCTs in Newly Diagnosed Stem Cell Transplantation Ineligible Multiple Myeloma Patients. Blood, 2016, 128, 2141-2141.	1.4	2
138	Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial). Blood, 2016, 128, 242-242.	1.4	26
139	Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study Group. Blood, 2016, 128, 3117-3117.	1.4	4
140	Feasibility and Efficacy of Dose Adjusted Melphalan - Prednisone - Bortezomib (MPV) in Elderly Patients â‰¥ 75 Years of Age with Newly Diagnosed Multiple Myeloma; the Non-Randomised Phase II HOVON 123 Study. Blood, 2016, 128, 3305-3305.	1.4	4
141	HOVON 104; Results of First 25 Patients from a Multicenter, Multinational, Prospective Phase II Study of Bortezomib Based Induction Treatment Followed By Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Al Amyloidosis. Blood, 2016, 128, 4628-4628.	1.4	1
142	Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial). Blood, 2016, 128, 673-673.	1.4	29
143	Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial).. Journal of Clinical Oncology, 2016, 34, 8000-8000.	1.6	52
144	Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors. Oncotarget, 2016, 7, 74779-74796.	1.8	16

#	Article	IF	Citations
145	Consideration of Symptom Burden Based Treatment in PV and ET Patients: An Analysis By MPN International Quality of Life Study Group. Blood, 2016, 128, 5463-5463.	1.4	0
146	Superior Identification of Prognostic Relevant Copy Number Abnormalities By SNP-Based Genomic Arrays As Compared to Interphase FISH in Multiple Myeloma. Blood, 2016, 128, 4426-4426.	1.4	1
147	Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. Blood, 2015, 125, 449-456.	1.4	60
148	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood, 2015, 125, 2068-2074.	1.4	586
149	Pharmacodynamic monitoring of (immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis. Lupus Science and Medicine, 2015, 2, e000121.	2.7	8
150	Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology. Haematologica, 2015, 100, 677-682.	3.5	18
151	Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug Resistance Updates, 2015, 18, 18-35.	14.4	153
152	¹⁸F-FDG or 3â€²-Deoxy-3â€²-¹⁸F-Fluorothymidine to Detect Transformation of Follicular Lymphoma. Journal of Nuclear Medicine, 2015, 56, 216-221.	5.0	24
153	Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients. Haematologica, 2015, 100, e90-e92.	3.5	18
154	European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. Haematologica, 2015, 100, 1254-1266.	3.5	289
155	Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial. Blood, 2015, 126, 27-27.	1.4	28
156	Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs). Blood, 2015, 126, 4073-4073.	1.4	2
157	Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs. Blood, 2015, 126, 4080-4080.	1.4	3
158	Unmet Needs for Symptom Control in Essential Thrombocythemia with Front Line Therapy. Blood, 2015, 126, 5175-5175.	1.4	0
159	Validation of the EMC92/SKY92 Signature in HOVON-87/Nmsg-18: Gene Expression Based Prognostication Is Applicable in Elderly Patients with Newly Diagnosed Multiple Myeloma. Blood, 2015, 126, 2967-2967.	1.4	0
160	Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma (eNDMM) from Thalidomide. Blood, 2015, 126, 4245-4245.	1.4	0
161	M3P Sequencing Panel Identifies TP53 Mutational Status As a Prognostic Factor in Chemotherapy-Naive Multiple Myeloma. Blood, 2015, 126, 2984-2984.	1.4	0
162	Marcks Marks Resistance to Proteasome Inhibitors: Exocytosis of Polyubiquitinated Proteins in Bortezomib-Resistant Leukemia Cells. Blood, 2015, 126, 3712-3712.	1.4	0

#	Article	IF	Citations
163	The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. Haematologica, 2014, 99, 984-996.	3.5	124
164	Genomic amplification of MYC as double minutes in a patient with APL-like leukemia. Molecular Cytogenetics, 2014, 7, 67.	0.9	11
165	Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia. PLoS ONE, 2014, 9, e107587.	2.5	164
166	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncology, The, 2014, 15, 333-342.	10.7	256
167	Whole-Body Low-Dose Computed Tomography and Advanced Imaging Techniques for Multiple Myeloma Bone Disease. Clinical Cancer Research, 2014, 20, 5888-5897.	7.0	64
168	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology, The, 2014, 15, e538-e548.	10.7	3,343
169	Antileukemic Activity and Mechanism of Drug Resistance to the Marine Salinispora tropica Proteasome Inhibitor Salinosporamide A (Marizomib). Molecular Pharmacology, 2014, 86, 12-19.	2.3	39
170	Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. Leukemia Research, 2014, 38, 816-821.	0.8	12
171	Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924. Biochemical Pharmacology, 2014, 89, 43-51.	4.4	36
172	Age and aging in blood disorders: multiple myeloma. Haematologica, 2014, 99, 1133-1137.	3.5	50
173	Randomized Phase III Trial in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma Comparing Melphalan-Prednisone-Thalidomide Followed By Thalidomide Maintenance (MPT-T) Versus Melphalan-Prednisone-Lenalidomide Followed By Maintenance with Lenalidomide (MPR-R); A Joint Study of the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and the Nordic Myeloma Study Group (NMSG). Blood, 2014, 124, 179-179.	1.4	6
174	Rare Igh Translocations in Newly Diagnosed Multiple Myeloma (MM) Patients: Cytogenetic Characterization and Relevance on Prognosis. Blood, 2014, 124, 2042-2042.	1.4	1
175	Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma from Thalidomide. Blood, 2014, 124, 5702-5702.	1.4	0
176	Immunologic Recovery Following Consolidation with 90Yttrium Ibritumomab Tiuxetan (ZevalinÂ®)-BEAM and Autologous Stem Cell Transplantation for Transformed B Cell Non-Hodkginâ€™s Lymphoma. Blood, 2014, 124, 5882-5882.	1.4	0
177	Single Sample Application of the EMC92/SKY92 Signature Using the Mmprofiler. Blood, 2014, 124, 2026-2026.	1.4	0
178	Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica, 2013, 98, 980-987.	3.5	193
179	No Improvement Of Overall Survival After Extended Follow-Up Of Donor Versus No Donor Analysis Of Newly Diagnosed Myeloma Patients Included In The HOVON 50/54 Study. Blood, 2013, 122, 2132-2132.	1.4	2
180	Phase 1/2 Trial Of Lenalidomide In Combination With Cyclophosphamide and Prednisone (REP) In Patients With Lenalidomide-Refractory Multiple Myeloma (REPEAT-study). Blood, 2013, 122, 287-287.	1.4	2

#	Article	IF	Citations
181	Thalidomide Combined With High Dose Melphalan Improves Event Free and Overall Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-50 Trial. Blood, 2013, 122, 3332-3332.	1.4	2
182	Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma:Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial. Blood, 2013, 122, 404-404.	1.4	14
183	Myeloproliferative (MPN) Symptom Burden Response Thresholds: Assessment Of MPN-SAF TSS Quartiles As Potential Markers Of Symptom Response. Blood, 2013, 122, 4067-4067.	1.4	6
184	Insomnia, Quality Of Life and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG). Blood, 2013, 122, 4087-4087.	1.4	9
185	Sexuality Challenges, Intimacy, and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG). Blood, 2013, 122, 4088-4088.	1.4	6
186	Efficacy and Safety Of Fedratinib (SAR302503/TG101348) In Patients With Intermediate- Or High-Risk Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Or Post-Essential Thrombocythemia (ET) MF Previously Treated With Ruxolitinib: Interim Results From a Phase II Study (JAKARTA-2). Blood, 2013, 122, 661-661.	1.4	13
187	Dose Escalation Phase 2 Trial Of Carfilzomib Combined With Thalidomide and Low-Dose Dexamethason In Newly Diagnosed, Transplant Eligible Patients With Multiple Myeloma. A Trial Of The European Myeloma Network. Blood, 2013, 122, 688-688.	1.4	9
188	Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD).. Journal of Clinical Oncology, 2013, 31, 8517-8517.	1.6	6
189	The Novel Immunoproteasome Inhibitor PR-924: Anti-Leukemic Activity and Mechanisms Of Resistance. Blood, 2013, 122, 3841-3841.	1.4	1
190	Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial. Journal of Clinical Oncology, 2012, 30, 2946-2955.	1.6	735
191	The Myelofibrosis Symptom Burden (MF-SB): An International Phenotypic Cluster Analysis of 329 Patients. Blood, 2012, 120, 1731-1731.	1.4	2
192	Carfilzomib Combined with Thalidomide and Dexamethasone (CTD) Is an Highly Effective Induction and Consolidation Treatment in Newly Diagnosed Patients with Multiple Myeloma (MM) Who Are Transplant Candidate. Blood, 2012, 120, 333-333.	1.4	9
193	A Phase II Study of Vorinostat (MK-0683) in Patients with Polycythemia Vera and Essential Thrombocythemia. Blood, 2012, 120, 803-803.	1.4	4
194	An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF).. Blood, 2012, 120, 2844-2844.	1.4	3
195	Interferon-Î³-Induced Upregulation of Immunoproteasome Subunit Assembly Overcomes Bortezomib Resistance of Leukemia Cell Lines Harbouring Bortezomib-Induced Mutations in Constitutive PSMB5. Blood, 2012, 120, 1346-1346.	1.4	2
196	Is There a Need for Extensive Haemostatic Screening in Neurosurgical Patients Using Valproic Acid?. Blood, 2012, 120, 1137-1137.	1.4	6
197	Relation Between Cereblon Expression and Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Thalidomide. Blood, 2012, 120, 3973-3973.	1.4	0
198	Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Symptom Burden: Phenotypic Cluster Analysis Among an International Sample of 1,141 ET and PV Patients. Blood, 2012, 120, 1726-1726.	1.4	4

#	Article	IF	Citations
199	Cost-Effectiveness of Rituximab As Maintenance Treatment for Relapsed Follicular Lymphoma: Results of a Population Based Study. Blood, 2012, 120, 4277-4277.	1.4	0
200	Comparison of the Myleloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Across Nine Linguistic Translations Among an International Sample of 1,851 Myeloproliferative Neoplasm (MPN) Patients.. Blood, 2012, 120, 2852-2852.	1.4	0
201	The Myleloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Derived Total Symptom Score (TSS): An International Trial of 1433 Patients with Myeloproliferative Neoplasms (MPNs),. Blood, 2011, 118, 3839-3839.	1.4	4
202	A Phase 2 Multicenter Study of Siltuximab, An Anti-IL-6 Monoclonal Antibody, in Patients with Relapsed or Refractory Multiple Myeloma,. Blood, 2011, 118, 3971-3971.	1.4	3
203	Carfilzomib Combined with Thalidomide and Dexamethasone (CARTHADEX) As Induction Treatment Prior to High-Dose Melphalan (HDM) in Newly Diagnosed Patients with Multiple Myeloma (MM). A Trial of the European Myeloma Network EMN. Blood, 2011, 118, 633-633.	1.4	7
204	Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients. Blood, 2011, 118, 996-996.	1.4	3
205	Does 18F-Fluorodeoxyglucose Outperform 18F-Fluorothymidine When Using Positron Emission Tomography in Predicting Transformation of Indolent Non-Hodgkin's Lymphoma,. Blood, 2011, 118, 3658-3658.	1.4	0
206	Sensitivity of Pediatric Acute Leukemia Cells to Bortezomib and Epoxyketone-Based Proteasome Inhibitors: Correlations with Proteasome Subunit Expression. Blood, 2011, 118, 1513-1513.	1.4	1
207	Quantitative in-Vivo Monitoring of Bone Formation in Multiple Myeloma Patients Following Treatment with Bortezomib: A Pilot Study. Blood, 2011, 118, 2939-2939.	1.4	0
208	MicroRNA Profiling In Multiple Myeloma. Blood, 2010, 116, 302-302.	1.4	1
209	Accurate Detection of Residual Leukemic Stem Cells In Remission Bone Marrow Predicts Relapse In Acute Myeloid Leukemia Patients. Blood, 2010, 116, 759-759.	1.4	7
210	Combination of CD34/CD38 Immunophenotypes and Side Population (SP) Reveals the Putative Leukemia Stem Cell/Leukemia Initiating Cell In Acute Myeloid Leukemia.. Blood, 2010, 116, 1582-1582.	1.4	0
211	The Prognostic Value of CD34 Expression In Acute Myeloid Leukemia. A Mystery Solved. Blood, 2010, 116, 2725-2725.	1.4	2
212	Specificity of Markers of Leukemia Initiating Cells with a New Multiparameter Flow Cytometry Based Appraoch; Impact for Prognostic and Therapeutic Applications. Blood, 2010, 116, 1834-1834.	1.4	0
213	First Interim Analysis of HOVON 76: Lenalidomide Maintenance Following Non Myeloablative Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma.. Blood, 2009, 114, 2285-2285.	1.4	2
214	Leukemic Stem Cell Assessment in Remission Bone Marrow of Acute Myeloid Leukemia Patients Is a New Prognostic Parameter.. Blood, 2009, 114, 399-399.	1.4	3
215	Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma.. Blood, 2009, 114, 1790-1790.	1.4	0
216	No Harmful Impact of 90Yttrium-Ibritumomab Tiuxetan Combined with BEAM On Bone Marrow Microenvironment.. Blood, 2009, 114, 3538-3538.	1.4	3

#	Article	IF	Citations
217	Final Analysis of HOVON-50 Randomized Phase III Study on the Effect of Thalidomide Combined with Adriamycine, Dexamethasone (AD) and High Dose Melphalan (HDM) in Patients with Multiple Myeloma (MM). Blood, 2008, 112, 157-157.	1.4	8
218	High-Dose Therapy in AL Amyloidosis: A Prospective Phase II Study by the Dutch-Belgian Cooperative Group (HOVON). Blood, 2008, 112, 163-163.	1.4	2
219	High Leukemic Stem Cell Frequency in Remission Bone Marrow Predicts Poor Outcome in Acute Myeloid Leukemia. Blood, 2008, 112, 2537-2537.	1.4	1
220	Donor Versus No Donor Analysis of Newly Diagnosed Myeloma Patients Included in the HOVON 50/54 Study. Blood, 2008, 112, 461-461.	1.4	153
221	Melphalan + Prednisone Versus Melphalan + Prednisone + Thalidomide in Induction Therapy for Multiple Myeloma in Elderly Patients: Final Analysis of the Dutch Cooperative Group HOVON 49 Study. Blood, 2008, 112, 649-649.	1.4	28
222	Specific Detection of Aberrant and Normal Stem Cells in Acute Myeloid Leukemia Patients Opens the Way for Defining Highly Specific Targets for Stem Cell Therapy.. Blood, 2008, 112, 1353-1353.	1.4	0
223	Reduced supportive capacity of bone marrow stroma upon chemotherapy is mediated via changes in glycosaminoglycan profile. Matrix Biology, 2007, 26, 561-571.	3.6	9
224	Molecular Mechanisms of Bortezomib Resistance in Acute Lymphoblastic Leukemia Cells in Comparison with Multiple Myeloma Cells.. Blood, 2007, 110, 3469-3469.	1.4	1
225	Identification of a Small Subpopulation of Candidate Leukemia Initiating Cells within the Side Population (SP) of Patients with Acute Myeloid Leukemia.. Blood, 2007, 110, 4120-4120.	1.4	1
226	Acute Myeloid Leukemia Remission Bone Marrow Reveals the Presence of Malignant and Normal Side Population (SP) Stem Cells Whose Frequencies and Ratios Predict Clinical Outcome.. Blood, 2006, 108, 2314-2314.	1.4	1
227	In Acute Myeloid Leukemia Both Malignant and Normal Stem Cells Can Be Detected in Remission Bone Marrow.. Blood, 2006, 108, 2537-2537.	1.4	2
228	Identification of Primitive Subpopulations of Acute Myeloid Leukemia Side Population (SP) Stem Cells Defined by Differentiation Status and Malignant Character.. Blood, 2006, 108, 2538-2538.	1.4	1
229	Bone marrow stromal proteoglycans regulate megakaryocytic differentiation of human progenitor cells. Experimental Cell Research, 2004, 299, 383-392.	2.6	13
230	Conditioning Regimens in Stem Cell Transplantations Facilitate Homing by Increasing Bone Marrow SDF-1 through Induction of SDF-1 Gene Transcription.. Blood, 2004, 104, 4958-4958.	1.4	0
231	Biochemical Characterization and Gene Expression Profiling of Cytarabine Treated Stromal Fibroblasts Reveal Regulatory Mechanisms Affecting Hyaluronan and Heparan Sulfate Proteoglycans.. Blood, 2004, 104, 1304-1304.	1.4	0